Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017433 · ClinicalTrials.gov registry record · Phase 2
Arsenic Trioxide in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00017433: Clinical Trial Phase 2 study, sponsored by CTI BioPharma.
NCT00017433 is a Phase 2 study that was terminated before completion, run by CTI BioPharma. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017433, a Phase 2 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory stage II or stage III multiple myeloma.
Interventions
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-01 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017433
The ClinicalTrials.gov registry entry for NCT00017433 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT00017433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017433 about?
NCT00017433 is a clinical study titled "Arsenic Trioxide in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory stage II or stage III multiple myeloma.
What is the current status of trial NCT00017433?
This trial is currently terminated. It is a Phase 2 study. The study started on 2001-01. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00017433?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00017433?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.